000180794 001__ 180794
000180794 005__ 20240229145632.0
000180794 0247_ $$2doi$$a10.3390/biomedicines10071738
000180794 0247_ $$2pmid$$apmid:35885047
000180794 0247_ $$2altmetric$$aaltmetric:132861493
000180794 037__ $$aDKFZ-2022-01556
000180794 041__ $$aEnglish
000180794 082__ $$a570
000180794 1001_ $$0P:(DE-He78)7aa3ba111f340c5cfbed338d0d8fb4ca$$aElmadany, Nirmeen$$b0$$eFirst author$$udkfz
000180794 245__ $$aSite-Specific Considerations on Engineered T Cells for Malignant Gliomas.
000180794 260__ $$aBasel$$bMDPI$$c2022
000180794 3367_ $$2DRIVER$$aarticle
000180794 3367_ $$2DataCite$$aOutput Types/Journal article
000180794 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1698998203_23211$$xReview Article
000180794 3367_ $$2BibTeX$$aARTICLE
000180794 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000180794 3367_ $$00$$2EndNote$$aJournal Article
000180794 500__ $$a#EA:D170#LA:D170# / HI-TRON
000180794 520__ $$aImmunotherapy has revolutionized cancer treatment. Despite the recent advances in immunotherapeutic approaches for several tumor entities, limited response has been observed in malignant gliomas, including glioblastoma (GBM). Conversely, one of the emerging immunotherapeutic modalities is chimeric antigen receptors (CAR) T cell therapy, which demonstrated promising clinical responses in other solid tumors. Current pre-clinical and interventional clinical studies suggest improved efficacy when CAR-T cells are delivered locoregionally, rather than intravenously. In this review, we summarize possible CAR-T cell administration routes including locoregional therapy, systemic administration with and without focused ultrasound, direct intra-arterial drug delivery and nanoparticle-enhanced delivery in glioma. Moreover, we discuss published as well as ongoing and planned clinical trials involving CAR-T cell therapy in malignant glioma. With increasing neoadjuvant and/or adjuvant combinatorial immunotherapeutic concepts and modalities with specific modes of action for malignant glioma, selection of administration routes becomes increasingly important.
000180794 536__ $$0G:(DE-HGF)POF4-314$$a314 - Immunologie und Krebs (POF4-314)$$cPOF4-314$$fPOF IV$$x0
000180794 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000180794 650_7 $$2Other$$aCAR T cells
000180794 650_7 $$2Other$$aCARs
000180794 650_7 $$2Other$$aFUS
000180794 650_7 $$2Other$$aglioblastoma
000180794 650_7 $$2Other$$aglioma
000180794 650_7 $$2Other$$aintrathecal delivery
000180794 650_7 $$2Other$$ananotechnology
000180794 650_7 $$2Other$$asystemic delivery
000180794 7001_ $$0P:(DE-He78)98da1f9d3c5ced2d8867edfe9f681ddc$$aAlhalabi, Obada$$b1$$udkfz
000180794 7001_ $$0P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5$$aPlatten, Michael$$b2$$udkfz
000180794 7001_ $$0P:(DE-He78)e579130c57e8c686ed1c2dedfa595985$$aBunse, Lukas$$b3$$eLast author$$udkfz
000180794 773__ $$0PERI:(DE-600)2720867-9$$a10.3390/biomedicines10071738$$gVol. 10, no. 7, p. 1738 -$$n7$$p1738$$tBiomedicines$$v10$$x2227-9059$$y2022
000180794 909CO $$ooai:inrepo02.dkfz.de:180794$$pVDB
000180794 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7aa3ba111f340c5cfbed338d0d8fb4ca$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000180794 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)98da1f9d3c5ced2d8867edfe9f681ddc$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000180794 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000180794 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e579130c57e8c686ed1c2dedfa595985$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000180794 9131_ $$0G:(DE-HGF)POF4-314$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImmunologie und Krebs$$x0
000180794 9141_ $$y2022
000180794 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2020-08-22
000180794 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-08-22
000180794 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2020-08-22
000180794 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-08-22
000180794 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2020-08-22
000180794 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2020-08-22
000180794 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-11
000180794 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-11
000180794 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2022-01-07T14:28:55Z
000180794 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2022-01-07T14:28:55Z
000180794 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2022-01-07T14:28:55Z
000180794 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-11
000180794 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-11
000180794 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-11
000180794 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-11
000180794 9202_ $$0I:(DE-He78)D170-20160331$$kD170$$lKKE Neuroimmunologie und Hirntumorimmunologie$$x0
000180794 9201_ $$0I:(DE-He78)D170-20160331$$kD170$$lKKE Neuroimmunologie und Hirntumorimmunologie$$x0
000180794 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000180794 9201_ $$0I:(DE-He78)B067-20160331$$kB067$$lB067 Juniorgruppe Brain Tumor Translational Target$$x2
000180794 9200_ $$0I:(DE-He78)D170-20160331$$kD170$$lKKE Neuroimmunologie und Hirntumorimmunologie$$x0
000180794 980__ $$ajournal
000180794 980__ $$aVDB
000180794 980__ $$aI:(DE-He78)D170-20160331
000180794 980__ $$aI:(DE-He78)HD01-20160331
000180794 980__ $$aI:(DE-He78)B067-20160331
000180794 980__ $$aUNRESTRICTED